从非酒精性脂肪性肝病到代谢性脂肪性肝病——基于疾病异质性角度的分析

冯巩; 严琴琴; 贺娜; 弥曼

doi:10.3969/j.issn.1001-5256.2020.11.045

从非酒精性脂肪性肝病到代谢性脂肪性肝病——基于疾病异质性角度的分析

DOI: 10.3969/j.issn.1001-5256.2020.11.045

1.
西安医学院全科医学研究所, 西安 710021
2.
西安医院第一附属医院消化内科，西安 710021

基金项目:

佑安感染病专科医疗联盟科研专项基金 (LM202003);

2020陕西省高等教育学会“疫情防控专项研究课题 (XGH20043)

详细信息

中图分类号: R575.5
计量
- 文章访问数: 475
- HTML全文浏览量: 22
- PDF下载量: 121
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-30
- 出版日期: 2020-11-20

From nonalcoholic fatty liver disease to metabolic fatty liver disease:An analysis based on disease heterogeneity

1.
Institute of General Practice, Xi’an Medical University, Xi’an 710021, China
2.
Department of Gastroenterology, The First Affiliated Hospital of Xi’an Medical University, Xi’an 710021, China

摘要

摘要:
非酒精性脂肪性肝病（NAFLD）已成为全球第一大慢性肝病,然而目前没有批准的药物用于临床实践。由于NAFLD本身异质性等原因,虽然药物疗法正在开发中,但应答率似乎不高。为了满足临床试验设计和为药物开发者提供准确信息等需要,相关学者建议将NAFLD改名为代谢性脂肪性肝病（MAFLD）。总结了NAFLD异质性的来源以及NAFLD更名的背景,从而为新治疗方法的研发提供新的思路。
- 非酒精性脂肪性肝病 /
- 代谢性脂肪性肝病 /
- 异质性
Abstract:
Nonalcoholic fatty liver disease( NAFLD) has become the most important chronic liver disease in the world,but there is still no approved drug for clinical practice. Due to the heterogeneity of NAFLD itself,although drug therapy is being developed,the response rate seems to remain low. In order to meet the needs of clinical trial design and provide accurate information for drug developers,relevant scholars have proposed to change the name of NAFLD to metabolic associated fatty liver disease This article summarizes the origin of NAFLD heterogeneity and the background of NAFLD renaming,so as to provide new ideas for accelerating the development of new therapies.
- non-alcoholic fatty liver disease /
- metabolic fatty liver disease /
- heterogeneity

HTML全文

参考文献(51)

[1] LUDWIG J,VIGGIANO TR,MCGILL DB,et al. Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc,1980,55(7):434-438.

[2] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.

[3] BUZZETTI E,PINZANI M,TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism,2016,65(8):1038-1048.

[4] SKOIEN R,RICHARDSON MM,JONSSON JR,et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways[J].Liver Int,2013,33(4):624-632.

[5] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.

[6] MCPHERSON S,HARDY T,DUFOUR JF,et al. Age as a Confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis[J]. Am J Gastroenterol,2017,112(5):740-751.

[7] de SILVA S,LI W,KEMOS P,et al. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent[J]. Frontline Gastroenterol,2018,9(2):115-121.

[8] DREW L. Development pipeline review 2018[J]. Nature,2017,551(2):s86-s89.

[9] FRIEDMAN SL,NEUSCHWANDER-TETRI BA,RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.

[10] YKI-JARVINEN H,LUUKKONEN PK. Heterogeneity of non-alcoholic fatty liver disease[J]. Liver Int,2015,35(12):2498-2500.

[11] LONARDO A,BALLESTRI S,TARGHER G．“Not all forms of NAFLD were created equal”. Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?[J]. Atherosclerosis,2017,257:253-255.

[12] ADAMS LA,LYMP JF,ST SAUVER J,et al. The natural history of nonalcoholic fatty liver disease:A population-based cohort study[J]. Gastroenterology,2005,129(1):113-121.

[13] ANGULO P,KLEINER DE,DAM-LARSEN S,et al. Liver fibrosis,but no other histologic features,is associated with longterm outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2015,149(2):389-397. e10.

[14] VILAR-GOMEZ E,CALZADILLA-BERTOT L,WAI-SUN WONG V,et al. Fibrosis severity as a determinant of causespecific mortality in patients with advanced nonalcoholic fatty liver disease:A multi-national cohort study[J]. Gastroenterology,2018,155(2):443-457. e17.

[15] SINGH S,ALLEN AM,WANG Z,et al. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies[J]. Clin Gastroenterol Hepatol,2015,13(4):643-654.

[16] VILAR-GOMEZ E,MARTINEZ-PEREZ Y,CALZADILLA-BERTOT L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology,2015,149(2):367-378. e5; quiz e14-15.

[17] LOOMBA R,ABRAHAM M,UNALP A,et al. Association between diabetes,family history of diabetes,and risk of nonalcoholic steatohepatitis and fibrosis[J]. Hepatology,2012,56(3):943-951.

[18] PELUSI S,CESPIATI A,RAMETTA R,et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis[J]. Clin Gastroenterol Hepatol,2019,17(11):2310-2319. e6.

[19] FRITH J,DAY CP,HENDERSON E,et al. Non-alcoholic fatty liver disease in older people[J]. Gerontology,2009,55(6):607-613.

[20] DONATI B,VALENTI L. Telomeres,NAFLD and chronic liver disease[J]. Int J Mol Sci,2016,17(3):383.

[21] PAPATHEODORIDI AM,CHRYSAVGIS L,KOUTSILIERIS M,et al. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis[J]. Hepatology,2020,71(1):363-374.

[22] KUK JL,SAUNDERS TJ,DAVIDSON LE,et al. Age-related changes in total and regional fat distribution[J]. Ageing Res Rev,2009,8(4):339-348.

[23] CHURILLA JR,FITZHUGH EC,THOMPSON DL. The metabolic syndrome:How definition impacts the prevalence and risk in U. S. adults:1999-2004 NHANES[J]. Metab Syndr Relat Disord,2007,5(4):331-342.

[24] LEE YH,JUNG KS,KIM SU,et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance:Nationwide surveys(KNHANES 2008-2011)[J]. J Hepatol,2015,63(2):486-493.

[25] LEE YH,KIM SU,SONG K,et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease:Nationwide surveys(KNHANES 2008-2011)[J]. Hepatology,2016,63(3):776-786.

[26] LONARDO A,NASCIMBENI F,BALLESTRI S,et al. Sex differences in nonalcoholic fatty liver disease:State of the art and identification of research gaps[J]. Hepatology,2019,70(4):1457-1469.

[27] ANDERSON EL,HOWE LD,JONES HE,et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents:A systematic review and Meta-analysis[J]. PLo S One,2015,10(10):e0140908.

[28] YANG JD,SUZUKI A. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease reply[J]. Hepatology,2014,60(5):1792-1793.

[29] MARIN V,ROSSO N,DAL BEN M,et al. An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. PLo S One,2016,11(7):e0158817.

[30] RICH NE,OJI S,MUFTI AR,et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence,severity,and outcomes in the United States:A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol,2018,16(2):198-210. e2.

[31] ZHOU F,ZHOU J,WANG W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and Meta-analysis[J]. Hepatology,2019,70(4):1119-1133.

[32] TABIBIAN JH,LAZO M,DURAZO FA,et al. Nonalcoholic fatty liver disease across ethno-racial groups:Do Asian-American adults represent a new at-risk population?[J]. J Gastroenterol Hepatol,2011,26(3):501-509.

[33] VANWAGNER LB,NING H,ALLEN NB,et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2017,153(5):1260-1272. e3.

[34] CHANG Y,CHO YK,KIM Y,et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease:A Cohort study[J]. Hepatology,2019,69(1):64-75.

[35] CAUSSY C,LOOMBA R. Gut microbiome,microbial metabolites and the development of NAFLD[J]. Nat Rev Gastroenterol Hepatol,2018,15(12):719-720.

[36] ARAB JP,KARPEN SJ,DAWSON PA,et al. Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.

[37] DING C,CHAN Z,MAGKOS F. Lean,but not healthy:the'metabolically obese,normal-weight’phenotype[J]. Curr Opin Clin Nutr Metab Care,2016,19(6):408-417.

[38] HAGSTROM H,NASR P,EKSTEDT M,et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease:A long-term follow-up study[J]. Hepatol Commun,2018,2(1):48-57.

[39] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.

[40] FRACANZANI AL,PETTA S,LOMBARDI R,et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease,and association with visceral obesity[J]. Clin Gastroenterol Hepatol,2017,15(10):1604-1611. e1.

[41] CHEN F,ESMAILI S,ROGERS GB,et al. Lean NAFLD:A distinct entity shaped by differential metabolic adaptation[J].Hepatology,2020,71(4):1213-1227.

[42] LOOMBA R,SCHORK N,CHEN CH,et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study[J]. Gastroenterology,2015,149(7):1784-1793.

[43] STRUBEN VM,HESPENHEIDE EE,CALDWELL SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds[J]. Am J Med,2000,108(1):9-13.

[44] CAUSSY C,SONI M,CUI J,et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis[J]. J Clin Invest,2017,127(7):2697-2704.

[45] LIU CH,AMPUERO J,GIL-GOMEZ A,et al. miRNAs in patients with non-alcoholic fatty liver disease:A systematic review and meta-analysis[J]. J Hepatol,2018,69(6):1335-1348.

[46] ATANASOVSKA B,RENSEN SS,VAN DER SIJDE MR,et al.A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis[J]. Hepatology,2017,66(3):794-808.

[47] ZHAO XY,XIONG X,LIU T,et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis[J]. Nat Commun,2018,9(1):2986.

[48] SOOKOIAN S,FLICHMAN D,GARAYCOECHEA ME,et al.Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage[J]. Hepatol Commun,2018,2(6):654-665.

[49] HARDY T,ZEYBEL M,DAY CP,et al. Plasma DNA methylation:A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease[J]. Gut,2017,66(7):1321-1328.

[50] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.

[51] GU J,LIU S,DU S,et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:A meta-analysis[J]. Eur Radiol,2019,29(7):3564-3573.

施引文献

资源附件(0)

访问统计